Ireland
--:--IST
Recruiting Observational

Busulfan Sample Collection Study

NCT05711732 · tracked via the Priya Life Science USA tracker
Sponsor
Saladax Biomedical, Inc
Phase
Observational
Started
2024-02-08
Last updated
2026-07-30

Condition(s) studied

Subjects Treated With Busulfan

Investigational drug(s) / intervention(s)

MyCare Oncology Busulfan Assay Kit

MyCare Oncology Busulfan Assay Kit: This is a sample collection study only. Patient treatment will not be determined by the outcome of the analytical test results.

Study summary

Busulfan (Busulfex®) is an alkylating drug used as a conditioning regimen prior to allogeneic hematopoietic stem cell transplantation. Busulfan has wide inter- and intra-patient pharmacokinetic variability resulting in variable exposure leading to increased risk of toxicities or sub-optimal treatment outcomes. Therapeutic drug monitoring of busulfan using patient plasma samples would benefit clinicians by providing the ability to personalize the dose to achieve a target busulfan exposure.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Pediatric and adult female or male subjects; 2. Current treatment with intravenous busulfan with documentation of diagnosed malignant hematologic or non-malignant disease condition requiring treatment; 3. Adult participants must be capable of understanding and providing written informed consent, approved by an Institutional Review Board (IRB) prior to the initiation of any screening or study-specific procedures. Participants less than 18 years old must provide written assent with appropriate consent provided by legal guardian, who must be capable of understanding and providing informed consent, per Institutional Review Board (IRB) procedures, prior to the initiation of any screening or study-specific procedures. Exclusion Criteria: 1. Unwilling or unable to follow protocol requirements or to give written informed consent; 2. Patients receiving oral busulfan (e.g., Myleran®) treatment.

Primary outcome measure(s)

  • Method Comparison Study — Sample collection to take place over 1 year. Samples to be analyzed monthly.
    The samples being collected according to the protocol, SBI-BSI-001, will be used to compare the quantitate determination of BSF in patient samples based on the immunoassay vs. LC-MS/MS methods .

Trial sites (3)

FacilityCityRegionStatus
Robert H. Lurie Comprehensive Cancer Center of Northwestern University Chicago Illinois Active Not Recruiting
Rutgers Cancer Institute New Brunswick New Jersey Recruiting
The University of Texas MD Anderson Cancer Center Houston Texas Active Not Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05711732 on ClinicalTrials.gov ↗ ← All trials in the USA